InterMune reports positive trial results By: MarketMinute.com Stock News May 19, 2014 at 13:37 PM EDT InterMune Inc. (Nasdaq: ITMN) reported positive results from an ASCEND phase III study of pirfenidone sending the stock price soaring $4.98 to $39.29.